Luye Pharma Group Past Earnings Performance

Past criteria checks 1/6

Luye Pharma Group's earnings have been declining at an average annual rate of -35.5%, while the Pharmaceuticals industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 0.1% per year. Luye Pharma Group's return on equity is 4%, and it has net margins of 8.7%.

Key information

-35.5%

Earnings growth rate

-37.9%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate-0.1%
Return on equity4.0%
Net Margin8.7%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Luye Pharma Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSC:2186 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 236,1435332,7000
30 Sep 236,0894952,7050
30 Jun 236,0354582,7110
31 Mar 236,0085312,5570
31 Dec 225,9826052,4030
30 Sep 225,5411902,3650
30 Jun 225,099-2242,3270
31 Mar 225,150-1792,3010
31 Dec 215,200-1342,2760
30 Sep 215,3652102,1960
30 Jun 215,5295542,1160
31 Mar 215,5346302,1510
31 Dec 205,5407072,1850
30 Sep 205,8649552,3020
30 Jun 206,1891,2042,4190
31 Mar 206,2731,3002,4910
31 Dec 196,3581,3962,5640
30 Sep 196,2291,4342,5060
30 Jun 196,1011,4722,4480
31 Mar 195,6371,3882,2870
31 Dec 185,1731,3032,1270
30 Sep 184,6711,2311,9570
30 Jun 184,1681,1591,7870
31 Mar 183,9911,0701,7530
31 Dec 173,8159811,7180
30 Sep 173,5479171,6290
30 Jun 173,2808521,5390
31 Mar 173,0998721,4640
31 Dec 162,9188921,3890
30 Sep 162,7848431,3100
30 Jun 162,6497941,2320
31 Mar 162,6067741,1900
31 Dec 152,5637551,1490
30 Sep 152,4817321,0370
30 Jun 152,4007109240
31 Mar 152,4726581,0460
31 Dec 142,5446061,1680
30 Sep 142,7055341,4150
30 Jun 142,8664621,6610
31 Mar 142,6903861,5930
31 Dec 132,5153101,5250
30 Jun 132,3082121,4630

Quality Earnings: 2186 has high quality earnings.

Growing Profit Margin: 2186's current net profit margins (8.7%) are lower than last year (10.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2186's earnings have declined by 35.5% per year over the past 5 years.

Accelerating Growth: 2186's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 2186 had negative earnings growth (-11.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (1.3%).


Return on Equity

High ROE: 2186's Return on Equity (4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.